Clinical trial
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory…
NCT00109967 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00109967 |
|---|---|
| Title | CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Mantle Cell Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, temsirolimus |
| Enrollment | 71 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2009 |
| Completion | Mar 1, 2012 |
| First posted | May 4, 2005 |
| Last update posted | Apr 17, 2014 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: